By Colin Kellaher

 

Merck & Co. and Eisai Co. on Monday said the European Commission has approved the combination of the combination of Eisai's Lenvima and Merck's Keytruda in a pair of indications.

Merck, based in Kenilworth, N.J., and Tokyo-based Eisai said the approvals include the combination for the first-line treatment of adults with advanced renal cell carcinoma, the most common type of kidney cancer.

The companies said the combination is also now approved for adults with advanced or recurrent endometrial cancer who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who aren't candidates for curative surgery or radiation.

Eisai and Merck in March 2018 formed a collaboration to jointly develop, manufacture and commercialize Lenvima as monotherapy and in combination with Merck's blockbuster cancer drug Keytruda.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 29, 2021 07:13 ET (12:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Merck Charts.